Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy
- Conditions
- Liver Neoplasms
- Interventions
- Other: Remote ischemia preconditionOther: None remote ischemia precondition
- Registration Number
- NCT02168608
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Brief Summary
Remote ischemia precondition could protect the liver from ischemia reperfusion injury in patients undergoing hepatectomy.
- Detailed Description
Remote ischemia precondition (RIPC) had been proofed beneficial to ischemia reperfusion injury of heart, kidney, liver, brain and spinal cord in experimentation on animals. And the clinical studies of RIPC were mainly focused on heart, RIPC's protection effect on hepatic ischemia reperfusion injury in patients undergoing hepatectomy still remains unknown, So we designed this study to demonstrate the hypotheses.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- No other main organ diseases, American society of Anesthesiologists (ASA) classification Ⅰ-Ⅱ grade
- Selective hepatectomy, one time hepatic portal occlusion
- Child-Pugh A
- Peripheral vessels diseases
- Not the same surgical procedure as expected
- Administered anti-inflammatory drugs as glucocorticoid etc
- Diagnosed of diabetes
- History of liver surgery
- History of hepatic interventional therapy, radiofrequency therapy,radiotherapy and chemotherapy
- Refuse to join the research
- Patients with psychopathy
- Acute infection need antibiotic therapy
- Hepatic artery or portal vein embolism
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Remote ischemia precondition Remote ischemia precondition patients in this arm accepted RIPC procedure after induction of anesthesia None remote ischemia precondition None remote ischemia precondition patients in this arm didn't accept RIPC procedure after induction of anesthesia
- Primary Outcome Measures
Name Time Method survival rate 30 days postoperatively
- Secondary Outcome Measures
Name Time Method alanine aminotransferase (ALT) level in patients' blood 7 days postoperatively Examine the patients's blood sample for ALT level at 7 days postoperatively
aspartic transaminase (AST) level in patients' blood 7 days postoperatively Examine the patients's blood sample for AST level at 7 days postoperatively
complications 30 days postoperatively Number of participants with adverse events within 30 days postoperatively
Trial Locations
- Locations (1)
Eastern Hepatobiliary Surgery Hospital
🇨🇳Shanghai, Shanghai, China